# BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

> **NCT04162353** · PHASE1 · RECRUITING · sponsor: **iCell Gene Therapeutics** · enrollment: 12 (estimated)

## Conditions studied

- Multiple Myeloma in Relapse
- Refractory Multiple Myeloma
- Plasmacytoid; Lymphoma

## Interventions

- **BIOLOGICAL:** BCMA-CD19 cCAR T cells

## Key facts

- **NCT ID:** NCT04162353
- **Lead sponsor:** iCell Gene Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-07-01
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-09-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04162353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04162353, "BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04162353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*